Clinical Trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Study acronym: DeLLphi-312
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Protocol Amendment History 4 changes
notable Trial sites expanded: 158 -> 164 locations 2026-06-26
notable Trial sites expanded: 150 -> 153 locations 2026-05-06
notable Trial sites expanded: 142 -> 146 locations 2026-04-10
notable Trial sites expanded: 131 -> 140 locations 2026-03-31
Trial Details
NCT Number NCT07005128
Lead Sponsor Amgen
Collaborators: AstraZeneca
Conditions Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Enrollment 330 participants
Start Date 2025-08-18
Primary Completion 2029-01-04 (estimated)
Study Completion 2029-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-16